1. Siegel, RL, Miller, KD, Jemal, A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.
Google Scholar | Crossref | Medline2. Chen, WQ, Zuo, TT, Zheng, RS, Zeng, HM, Zhang, SW, He, J. Lung cancer incidence and mortality in China in 2013. Zhonghua Zhong Liu Za Zhi. 2017;39(10):795–800.
Google Scholar | Medline3. Ke, EE, Zhou, Q, Wu, YL. Emerging paradigms in targeted treatments for Asian patients with NSCLC. Expert Opin Pharmacother. 2015;16(8):1167–1176.
Google Scholar | Crossref | Medline4. Alberg, AJ, Brock, MV, Ford, JG, Samet, JM, Spivack, SD. Epidemiology of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 suppl):e1S–e29S.
Google Scholar | Crossref | Medline5. Shah, R, Lester, JF. Tyrosine kinase inhibitors for the treatment of EGFR mutation-positive non-small-cell lung cancer: a clash of the generations. Clin Lung Cancer. 2020;21(3):e216–e228.
Google Scholar | Crossref | Medline6. Chan, BA, Hughes, BG. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res. 2015;4(1):36–54.
Google Scholar | Medline | ISI7. Maemondo, M, Inoue, A, Kobayashi, K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380–2388.
Google Scholar | Crossref | Medline | ISI8. Mitsudomi, T, Morita, S, Yatabe, Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11(12):121–128.
Google Scholar | Crossref | Medline9. Zhou, C, Wu, YL, Chen, G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised phase 3 study. Lancet Oncol. 2011;12(8):735–742.
Google Scholar | Crossref | Medline | ISI10. Rosell, R, Carcereny, E, Gervais, R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–246.
Google Scholar | Crossref | Medline | ISI11. Thatcher, N, Chang, A, Parikh, P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005;366(9496):1527–1537.
Google Scholar | Crossref | Medline | ISI12. Kim, ES, Hirsh, V, Mok, T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet. 2008;372(9652):1809–1818.
Google Scholar | Crossref | Medline | ISI13. Ciuleanu, T, Stelmakh, L, Cicenas, S, et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol. 2012;13(3):300–308.
Google Scholar | Crossref | Medline14. Shepherd, FA, Rodrigues, PJ, Ciuleanu, T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2):123–132.
Google Scholar | Crossref | Medline | ISI15. Shepherd, FA, Douillard, J, Fulcuolca, M, et al. Comparison of gefitinib and docetaxel in patients with pretreated advanced non-small-cell lung cancer (NSCLC): meta-analysis from four clinical trials. J Clin Oncol. 2009;27(15 suppl):8011.
Google Scholar | Crossref16. Takeda, M, Nakagawa, K. First-and second-generation EGFR-TKIs are all replaced to osimertinib in chemo-naive EGFR mutation-positive non-small-cell lung cancer. Int J Mol Sci. 2019;20(1):146.
Google Scholar | Crossref17. Hu, S, Xie, G, Zhang, DX, et al. Synthesis and biological evaluation of crown ether fused quinazoline analogues as potent EGFR inhibitors. Bioorg Med Chem Lett. 2012;22(19):6301–6305.
Google Scholar | Crossref | Medline18. Fukuoka, M, Wu, YL, Thongprasert, S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011;29(21):2866–2874.
Google Scholar | Crossref | Medline | ISI19. Huang, J, Meng, L, Yang, B, Sun, S, Luo, Z, Chen, H. Safety profile of epidermal growth factor receptor tyrosine kinase inhibitors: a disproportionality analysis of FDA adverse event reporting system. Sci Rep. 2020;10(1):4803.
Google Scholar | Crossref | Medline20. Park, K, Tan, EH, O’Byrne, K, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016;17(5):577–589.
Google Scholar | Crossref | Medline | ISI21. He, H, Zhou, X, Wang, Q, Zhao, Y. Does the course of astragalus-containing Chinese herbal prescriptions and radiotherapy benefit to non-small-cell lung cancer treatment: a meta-analysis of randomized trials. Evid Based Complement Alternat Med. 2013;2013:426207.
Google Scholar | Crossref | Medline | ISI22. Feng, F, Huang, J, Wang, Z, et al. Xiao-ai-ping injection adjunct with platinum-based chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis. BMC Complement Med Ther. 2020;20(1):3.
Google Scholar | Crossref | Medline23. Cao, A, He, H, Jing, M, Yu, B, Zhou, X. Shenfu injection adjunct with platinum-based chemotherapy for the treatment of advanced non-small-cell lung cancer: a meta-analysis and systematic review. Evid Based Complement Alternat Med. 2017;2017:1068751.
Google Scholar | Crossref | Medline24. Wang, Z, Feng, F, Wu, Q, et al. Disodium cantharidinate and vitamin B6 injection adjunct with platinum-based chemotherapy for the treatment of advanced non-small-cell lung cancer: a meta-analysis. Evid Based Complement Alternat Med. 2019;2019:9386273.
Google Scholar | Medline25. Xiong, SQ, Li, YL, Wang, SM, et al. Cohort study of EGFR-TKIs combined with traditional Chinese medicine and single EGFR-TKIs for advanced NSCLC (non-small cell lung cancer). Sichuan Da Xue Xue Bao Yi Xue Ban. 2018;49(4):566–569.
Google Scholar | Medline26. Jiao, L, Xu, J, Sun, J, et al. Chinese herbal medicine combined with EGFR-TKI in EGFR mutation-positive advanced pulmonary adenocarcinoma (CATLA): a multicenter, randomized, double-blind, placebo-controlled trial. Front Pharmacol. 2019;10:732.
Google Scholar | Crossref | Medline27. He, W, Cheng, M. Meta-analysis on effectiveness and safety of traditional Chinese medicine combined with first-generation EGFR-TKI in treating advanced non-small-cell lung cancer. Zhongguo Zhong Yao Za Zhi. 2017;42(13):2591–2598.
Google Scholar | Medline28. Tang, M, Wang, S, Zhao, B, et al. Traditional Chinese Medicine Prolongs Progression-Free Survival and Enhances Therapeutic Effects in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) treated non-small-cell lung cancer (NSCLC) patients harboring EGFR mutations. Med Sci Monit. 2019;25:8430–8437.
Google Scholar | Crossref | Medline29. Xie, G, Cui, Z, Peng, K, Zhou, X, Xia, Q, Xu, D. Aidi injection, a traditional Chinese medicine injection, could be used as an adjuvant drug to improve quality of life of cancer patients receiving chemotherapy: a propensity score matching analysis. Integr Cancer Ther. 2019;18:1534735418810799.
Google Scholar | SAGE Journals | ISI30. Xiao, Z, Jiang, Y, Wang, CQ, et al. Clinical efficacy and safety of Aidi injection combination with vinorelbine and cisplatin for advanced non-small-cell lung carcinoma: a systematic review and meta-analysis of 54 randomized controlled trials. Pharmacol Res. 2020;153:104637.
Google Scholar | Crossref | Medline31. Xiao, Z, Wang, C, Chen, L, et al. Has Aidi injection the attenuation and synergistic efficacy to gemcitabine and cisplatin in non-small-cell lung cancer? A meta-analysis of 36 randomized controlled trials. Oncotarget. 2017;8(1):1329–1342.
Google Scholar | Crossref | Medline32. Wang, J, Li, G, Yu, L, Mo, T, Wu, Q, Zhou, Z. Aidi injection plus platinum-based chemotherapy for stage IIIB/IV non-small-cell lung cancer: a meta-analysis of 42 RCTs following the PRISMA guidelines. J Ethnopharmacol. 2018;221:137–150.
Google Scholar | Crossref | Medline33. Xiao, Z, Wang, C, Sun, Y, et al. Can Aidi injection restore cellular immunity and improve clinical efficacy in non-small-cell lung cancer patients treated with platinum-based chemotherapy? A meta-analysis of 17 randomized controlled trials following the PRISMA guidelines. Medicine (Baltimore). 2016;95(44):e5210.
Google Scholar | Crossref | Medline34. Fang, H . Clinical observation of gefitinib combination with Aidi injection in treatment of advanced on small-cell lung cancer. Jiankang Bidu. 2011;8:28–29.
Google Scholar35. Jiang, J, Lang, X, Yu, S, Qian, X, Yin, W, Li, L. Clinical efficacy of Aidi injection combined with gefitinib in the treatment of patients with advanced EGFR gene mutation lung cancer. Contemp Med. 2019;25:97–99.
Google Scholar36. Shen, Q, Liu, W. Clinical study of Ektinib combined with Aidi injection in treatment of non-small-cell lung cancer. Drug Evaluat Res. 2019;42:2210–2213.
Google Scholar37. Wang, T, Ouyang, C, Yang, L, Chen, Z, Gu, H. Effect of Aidi injection combined with gefitinib on tumor markers in patients with non-small-cell lung cancer. Chin Pharm. 2018;27:32–35.
Google Scholar38. Wen, F, Xiang, Y, Wang, S. Effect of application of markers and immune function of patients with tumor of erlotinib combined with Addie injection in non-small-cell lung cancer. J Hainan Med Univ. 2018;24(9):949–952.
Google Scholar39. Zhang, L, Han, N, Ding, Y, Zhang, J, Feng, G. Clinical observation of gefitinib tablets combined with Aidie injection in the treatment of advanced non-small-cell lung cancer with EGFR Positive. Prog Modern Biomed. 2018;18:2696–2700.
Google Scholar40. Liang, J, Li, B, Li, J, Wu, L. Clinical observation of gefitnib combination with Aidi injection in the treatment of 80 advanced non-small-cell lung cancer patients. Chinese Remedies & Clinics. 2014;14:957–959.
Google Scholar41. Fei, W, Song, LI. Effects of Aidi injection combined with erlotinib on T lymphocytes, vascular endothelial growth factor and quality of life in patients with advanced non-small cell-lung cancer. World Clinic Drugs. 2020;41:301–306.
Google Scholar42. World Health Organization . WHO Handbook for Reporting Results of Cancer. World Health Organization; 1979.
Google Scholar43. Higgins, JPT, Thomas, J, Chandler, J, Cumpston, M, Li, T, Page, MJ. Cochrane Handbook for Systematic Reviews of Interventions. 2nd ed. John Wiley & Sons; 2019.
Google Scholar | Crossref44. Liu, T, Zuo, L, Guo, D, et al. Ginsenoside Rg3 regulates DNA damage in non-small-cell lung cancer cells by activating VRK1/P53BP1 pathway. Biomed Pharmacother. 2019;120:109483.
Google Scholar45. Li, Y, Wang, Y, Niu, K, et al. Clinical benefit from EGFR-TKI plus ginsenoside Rg3 in patients with advanced non-small-cell lung cancer harboring EGFR active mutation. Oncotarget. 2016;7(43):70535–70545.
Google Scholar | Crossref | Medline46. Wang, XJ, Zhou, RJ, Zhang, N, Jing, Z. 20(S)-ginsenoside Rg3 sensitizes human non-small-cell lung cancer cells to icotinib through inhibition of autophagy. Eur J Pharmacol. 2019;850:141–149.
Google Scholar | Crossref | Medline47. Huang, Q, Wang, Q, Li, D, et al. Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small-cell lung cancer. J Exp Clin Cancer Res. 2019;38(1):129.
Google Scholar | Crossref | Medline48. Wang, X, Li, Y, Liu, D, Wang, Y, Ming, HX. Effect of astragalus polysaccharide on autophagy and PI3K/AKT signaling pathway in lung cancer A549 cells induced by xanthine oxidase. Chin Pharmacol Bull. 2019;35:1676–1680.
Google Scholar49. Liu, YP, Li, L, Xu, L, Dai, EN, Chen, WD. Cantharidin suppresses cell growth and migration, and activates autophagy in human non-small-cell lung cancer cells. Oncol Lett. 2018;15(5):6527–6532.
Google Scholar | Medline50. Sun, D, Chen, J, Hu, H, et al. Acanthopanax senticosus polysaccharide suppressing proliferation and metastasis of the human non-small-cell lung cancer NCI-H520 cells is associated with Wnt/β-catenin signaling. Neoplasma. 2019;66(4):555–563.